Filter By
Clear all Advanced
I am/have/had
added new label for I am/have/had
more
I am looking for
added new label for I am looking for
more
Advanced Filters
Found 51 clinical trials
Pembrolizumab, Lenvatinib and Chemotherapy After TKIs in NSCLC

combination pembrolizumab with lenvatinib and chemotherapy in NSCLC patients with sensitizing EGFR, ALK, or ROS1 genetic aberration refractory to standard targeted therapy.

pemetrexed
cancer chemotherapy
carboplatin
pembrolizumab
proto-oncogene tyrosine-protein kinase ros
  • 0 views
  • 18 Dec, 2021
  • 1 location
NCI-COG Pediatric MATCH (Molecular Analysis for Therapy Choice)- Phase 2 Subprotocol of Ensartinib in Patients With Tumors Harboring ALK or ROS1 Genomic Alterations

This phase II Pediatric MATCH trial studies how well ensartinib works in treating patients with solid tumors, non-Hodgkin lymphoma, or histiocytic disorders with ALK or ROS1 genomic alterations

nitrosoureas
cancer therapy
chemotherapeutic agents
radiopharmaceutical therapy
platelet count
  • 68 views
  • 22 Oct, 2022
  • 73 locations
Cabozantinib in Patients With RET Fusion-Positive Advanced Non-Small Cell Lung Cancer and Those With Other Genotypes: ROS1 or NTRK Fusions or Increased MET or AXL Activity

The purpose of this phase II study is to find out what effects cabozantinib (XL184) has, good and/or bad, in patients whose tumors one of the following gene changes RET, ROS1, or NTRK fusion, or

NTRK
lung carcinoma
cancer chemotherapy
RET
proto-oncogene tyrosine-protein kinase ros
  • 62 views
  • 10 Jul, 2022
  • 7 locations
A Study Evaluating Platinum-Pemetrexed-Atezolizumab (+/-Bevacizumab) for Patients With Stage IIIB/IV Non-squamous Non-small Cell Lung Cancer With EGFR Mutations ALK Rearrangement or ROS1 Fusion Progressing After Targeted Therapies

The objective of this study is to assess the efficacy of the combination of Platinum (carboplatin or cisplatin), Pemetrexed, Atezolizumab+/- Bevacizumab if eligible, in stage IIIB/IV non-squamous non-small cell lung cancer patients with progression-enhancing mutations following targeted therapies.

  • 0 views
  • 19 Jun, 2021
  • 30 locations
LORLATINIB (PF-06463922) CONTINUATION PROTOCOL: AN OPEN-LABEL, SINGLE-ARM CONTINUATION STUDY FOR PARTICIPANTS WITH ALK-POSITIVE OR ROS1-POSITIVE NON-SMALL CELL LUNG CANCER (NSCLC) CONTINUING FROM PFIZER SPONSORED LORLATINIB CLINICAL STUDIES

The purpose of this protocol is to provide continued treatment access and safety follow-up for eligible participants who continue to derive a benefit from study intervention in the Pfizer sponsored lorlatinib parent studies that will be closed. Additional follow-up safety data collection will permit further characterization of the safety profile …

  • 0 views
  • 21 Oct, 2022
  • 4 locations
TGRX-326 Chinese Phase I for Advanced Non-small Cell Lung Cancer (NSCLC)

safety, tolerability, PK and preliminary efficacy of TGRX-326 in patients with ALK-positive or ROS1-positive advanced NSCLC.

proto-oncogene tyrosine-protein kinase ros
lung carcinoma
alopecia
targeted therapy
ROS1
  • 0 views
  • 04 Oct, 2022
  • 1 location
Lorlatinib Combinations in Lung Cancer

ROS1-positive lung cancer. This research study involves four study drugs. Lorlatinib Binimetinib Crizotinib TNO155

lung carcinoma
cancer chemotherapy
leptomeningeal disease
ros1 rearrangement
lung cancer
  • 0 views
  • 19 Mar, 2021
Efficacy and Safety of PVT-1 Treatment in Patients With Advanced Non-Small Cell Lung Cancer

refractory to existing treatments. In NSCLC the molecular profile is important to direct the treatment. Specifically, for cases with an EGFR+, ALK+, ROS1+ or PD1/PDL1+ molecular profile, targeted

brain metastases
proto-oncogene tyrosine-protein kinase ros
ct scan
lung carcinoma
cancer chemotherapy
  • 0 views
  • 26 May, 2022
  • 4 locations
Genetic Testing in Guiding Treatment for Patients With Brain Metastases

mutated in brain metastases such as NTRK, ROS1, CDK or PI3K. Medications that target these genes such as abemaciclib, paxalisib, and entrectinib may stop the growth of tumor cells by blocking some of the

  • 146 views
  • 14 Jun, 2022
  • 170 locations
WX-0593 Combined With Concurrent Chemoradiotherapy in Unresectable Locally Advanced NSCLC

mutation of ALK or ROS1. This trial consists of two parts. In Part 1, approximately 8 patients will be included and receive WX-0593 maintenance until disease progression or unacceptable toxicity. In Part 2

proto-oncogene tyrosine-protein kinase ros
lung carcinoma
cancer chemotherapy
chemoradiotherapy
ROS1
  • 0 views
  • 16 May, 2022
  • 1 location